AIM Vaccine (HKG:6660) said its unit Liverna Therapeutics developed mRNA respiratory syncytial virus (RSV) vaccine was approved by China's National Medical Products Administration for clinical trial, according to a Wednesday filing with the Hong Kong bourse.
RSV is a highly contagious, common respiratory tract infection pathogen that causes death in infants under one year old, the filing said.
The company's shares were up by over 2% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.